Literature DB >> 3007374

Virus production and surface marker expression in human lymphocytes immortalized following dual infection with human T-cell leukemia virus and Epstein-Barr virus.

S Mochizuki, K Kawamura, K Maruyama.   

Abstract

By co-cultivating peripheral blood lymphocytes from normal male donors with cells from a line designated Lma-66VP, established from a female donor and simultaneously producing both HTLV-I and EBV, 2 continuous culture lines were obtained. Normal male lymphocytes were considered to be immortalized by co-cultivation because they were of male karyotype and lacked the 3q+ chromosome that was observed in all Lma-66VP cells. These immortalized cultures were designated Co-culture 1 and Co-culture 2. After prolonged cultivation, chromosome abnormalities characteristic of each co-culture line were observed in all cells examined, indicating their clonal origin. Immortalized cells initially produced both HTLV-I and EBV. Although production of EBV was not seen in the co-culture lines after prolonged cultivation when all cells examined had the characteristic chromosomal abnormality indicating their clonality, EBNA+ cells persisted. Thus, clonal cells were doubly infected by HTLV-I and EBV. While the majority of clonal cells in Lma-66VP, Co-culture 1, and Co-culture 2 lines expressed a surface marker of B-cells, small numbers of cells expressed a T-cell surface marker. These findings demonstrate that human lymphocytes immortalized following dual infection by HTLV-I and EBV exhibit chromosome rearrangement, resulting in expression of surface markers inconsistent with their differentiation lineage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007374     DOI: 10.1002/ijc.2910370413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  1 in total

1.  Epstein-Barr virus in adult T-cell leukemia/lymphoma.

Authors:  M Tokunaga; S Imai; Y Uemura; T Tokudome; T Osato; E Sato
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.